A small Swiss biotech tackles a huge global health issue with a handoff from GSK. But can it make any money from it?
During the global pandemic, we got a good look at how a new technology can transform the vaccines market and earn billions of dollars in windfall profits from high-income countries. But it’s still a tricky market, with a huge need for vaccines directed at underserved communities of the world that are often simply neglected or spend years on the back burner of non-profit programs.
Take the Shigella bacteria, which can trigger lethal cases of shigellosis, spurring diarrhea in cases that spread from child to child, adult to adult, and killing around 600,000 people a year, largely in sub-Saharan Africa and South Asia.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.